Long-Acting, Short-Residing Nanochelators for Iron Overload Therapy
用于铁过载治疗的长效、短效纳米螯合剂
基本信息
- 批准号:10585319
- 负责人:
- 金额:$ 73.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:Adverse effectsAffectAgranulocytosisAnemiaAnimal ModelAnimalsArthritisBiochemicalBiological AvailabilityBloodBlood TransfusionCardiomyopathiesCaucasiansCessation of lifeChelating AgentsChelation TherapyChemistryChronicClinicalClinical TrialsColumn ChromatographyCommunicationContinuous InfusionCyclic GMPDeferoxamineDiabetes MellitusDialysis procedureDiamond-Blackfan anemiaDiseaseDoseDose LimitingDrug or chemical Tissue DistributionDyslipidemiasDysmyelopoietic SyndromesEngineeringExcisionExcretory functionFDA approvedFamily suidaeFerritinFormulationFreeze DryingFutureGastrointestinal HemorrhageGenetic DiseasesGrantHalf-LifeHeart failureHematopoieticHepaticHereditary hemochromatosisHydrogelsHypertriglyceridemiaHypotensionImpairmentInfectionInflammationInfusion proceduresInjectableInjectionsIntravenousIronIron Chelating AgentsIron ChelationIron OverloadKidneyKineticsLiverLiver CirrhosisLiver FailureLiver FibrosisMarketingMaximum Tolerated DoseMediatingMetabolic syndromeMetalsModelingMorbidity - disease rateMultimodal ImagingMusNational Heart, Lung, and Blood InstituteNatureNeurodegenerative DisordersNutritionalObesityOralOrganOrganic SynthesisOxidative StressOxidative Stress InductionPatientsPatternPersonsPlasmaPolymersPopulationPredispositionProceduresPublicationsRattusReactive Oxygen SpeciesReportingRisk FactorsRisk ReductionRodentSafetySickle Cell AnemiaSiteSolventsSubcutaneous InjectionsTabletsThalassemiaTherapeuticTissuesToxic effectToxicity TestsTransfusionTreatment EfficacyUnited States National Institutes of HealthUrineabsorptioncompliance behaviordesignefficacy evaluationheart damageheart functionimaging systemimmunogenicityimprovedinjection/infusioniron absorptionmilligrammortalitynanonephrotoxicitynovelnovel therapeutic interventionolder patientparenteral administrationprematureprototyperesidenceresponsescale upside effectsmall moleculestandard caresubcutaneoussystemic toxicitytherapy outcometreatment adherenceuptakeurinary
项目摘要
Project Summary/Abstract: Iron is an essential metal, but high iron stores are toxic due to increased oxidative
stress produced by iron-catalyzed reactive oxygen species. Increased iron stores are associated with well-
established risk factors of heart and liver failure, arthritis, dyslipidemia, and diabetes, including obesity, metabolic
syndrome, and chronic inflammation, particularly for patients who are genetically susceptible to developing iron
overload. Secondary iron overload occurs in several anemias (e.g., thalassemia, myelodysplastic syndrome,
sickle cell anemia, Diamond-Blackfan anemia) due to repeated transfusions, and increased absorption of iron
loading from repeated transfusions can be major causes of morbidity and mortality in chronic anemia patients.
There are three FDA-approved chelators in the U.S.: deferoxamine (Desferral, Novartis; IV/IM/SC injection),
deferasirox (Jadenu, Exjade; Novartis; oral tablet), and deferiprone (Ferriprox, ApoPharma; oral tablet/solution).
Since 1968, the prototype iron chelator deferoxamine has shown good therapeutic efficacy but requires repeated
injections or continuous infusions, which considerably decreases patient compliance. To overcome this issue,
two oral chelators have become available in the market (deferasirox in 2005 and deferiprone in 2011). Despite
their efficient iron chelation with improved patient compliance, oral chelators have shown significant dose-limiting
adverse effects. For example, deferasirox can cause gastrointestinal bleeding, which may be fatal in elderly
patients, in addition to hepatic and renal toxicities. These adverse effects occur because these small molecule
chelators demonstrate a higher tendency to distribute into non-target tissues, exerting toxicities. Furthermore,
clinicians report that a novel, more convenient, and better-tolerated delivery of the iron chelator would improve
treatment adherence and long-term therapeutic outcomes.
Previously, we have successfully developed a multifunctional nanochelator that captures iron from plasma
and liver, circulates without significant nonspecific uptake in non-target tissues, and leaves the body through
urinary excretion. Armed with this renal clearable nanochelator, we aim to develop subcutaneous injectable
hydrogel formulations with increased exposure for up to 3 weeks and with tracking the release kinetics using
multimodal imaging systems longitudinally. This strategy can decrease the iron burden and reduce the risk of
iron-mediated organ toxicity, with no overt chelator-related adverse effects. Therefore, our hypothesis is that a
thermosensitive injectable hydrogel, which offers a long-term sustained release of iron chelators but a short-term
residence in the major tissues/organs (i.e., rapid clearance upon iron chelation without accumulation), can
improve the therapeutic efficacy of iron chelation while minimizing chelator-induced toxicity, beyond the current
standard treatment of iron overload.
项目摘要/摘要:铁是一种必需的金属,但由于氧化性增加,高铁储存是有毒的。
由铁催化的活性氧物质产生的压力。铁含量的增加与
已确定的心脏和肝脏衰竭、关节炎、血脂异常和糖尿病的风险因素,包括肥胖、代谢性
综合征和慢性炎症,特别是对于遗传上易受铁生成影响的患者
超载。继发性铁超负荷发生在几种贫血中(例如,地中海贫血,骨髓增生异常综合征,
镰状细胞性贫血,Diamond-Blackfan贫血),由于反复输血和铁吸收增加
反复输血的负荷可能是慢性贫血患者发病和死亡的主要原因。
在美国有三种FDA批准的螯合剂:去铁胺(Desferral,Novartis; IV/IM/SC注射),
地拉罗司(Jadenu,Exjade; Novartis;口服片剂)和去铁酮(奥贝安可,ApoPharma;口服片剂/溶液)。
自1968年以来,原型铁螯合剂去铁胺已显示出良好的治疗效果,但需要重复
注射或连续输注,这大大降低了患者的依从性。为了克服这个问题,
市场上有两种口服螯合剂(2005年的地拉罗司和2011年的去铁酮)。尽管
口服螯合剂的有效的铁螯合作用和改善的患者依从性显示出显著的剂量限制性,
不良影响例如,地拉罗司可引起胃肠道出血,这对老年人可能是致命的。
患者,除了肝和肾毒性。这些不良反应的发生是因为这些小分子
螯合剂表现出更高的分布到非靶组织中的倾向,从而产生毒性。此外,委员会认为,
临床医生报告说,一种新的、更方便的和耐受性更好的铁螯合剂的递送将改善
治疗依从性和长期治疗结果。
此前,我们已经成功开发了一种多功能纳米螯合剂,可以从血浆中捕获铁
和肝脏,在非靶组织中循环而没有显著的非特异性摄取,并通过
尿排泄有了这种肾脏可清除的纳米螯合剂,我们的目标是开发皮下注射
增加暴露长达3周的水凝胶制剂,并使用
多模态成像系统纵向。这种策略可以减少铁负荷,降低
铁介导的器官毒性,没有明显的螯合剂相关的不良反应。因此,我们的假设是
温敏性可注射水凝胶,其提供铁螯合剂的长期持续释放,但提供铁螯合剂的短期释放。
在主要组织/器官中的驻留(即,铁螯合后快速清除而无蓄积),可
提高铁螯合的治疗效果,同时最大限度地减少螯合剂诱导的毒性,
铁超载的标准治疗
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hak Soo Choi其他文献
Hak Soo Choi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hak Soo Choi', 18)}}的其他基金
Nanochelation Therapies for Iron Overload Disorders
纳米螯合疗法治疗铁过载疾病
- 批准号:
10318332 - 财政年份:2021
- 资助金额:
$ 73.42万 - 项目类别:
Nanochelation Therapies for Iron Overload Disorders
纳米螯合疗法治疗铁过载疾病
- 批准号:
10437625 - 财政年份:2021
- 资助金额:
$ 73.42万 - 项目类别:
Image-Guided Drug Delivery and Treatment for GIST
图像引导胃肠道间质瘤的药物输送和治疗
- 批准号:
9792375 - 财政年份:2018
- 资助金额:
$ 73.42万 - 项目类别:
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.
图像引导胰腺神经内分泌肿瘤的药物输送。
- 批准号:
9302133 - 财政年份:2017
- 资助金额:
$ 73.42万 - 项目类别:
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor
图像引导胰腺神经内分泌肿瘤给药
- 批准号:
10167387 - 财政年份:2017
- 资助金额:
$ 73.42万 - 项目类别:
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.
图像引导胰腺神经内分泌肿瘤的药物输送。
- 批准号:
9566182 - 财政年份:2017
- 资助金额:
$ 73.42万 - 项目类别:
Ultra-Low Background NIR Fluorophores for In Vivo Imaging and Image-Guided Surger
用于体内成像和图像引导手术的超低背景近红外荧光团
- 批准号:
8514598 - 财政年份:2010
- 资助金额:
$ 73.42万 - 项目类别:
Ultra-Low Background NIR Fluorophores for In Vivo Imaging and Image-Guided Surger
用于体内成像和图像引导手术的超低背景近红外荧光团
- 批准号:
7937599 - 财政年份:2010
- 资助金额:
$ 73.42万 - 项目类别:
Ultra-Low Background NIR Fluorophores for In Vivo Imaging and Image-Guided Surger
用于体内成像和图像引导手术的超低背景近红外荧光团
- 批准号:
8112741 - 财政年份:2010
- 资助金额:
$ 73.42万 - 项目类别:
Image-Guided Surgery of Endocrine Glands and Their Tumors using Near-Infrared Flu
使用近红外流感图像引导内分泌腺及其肿瘤手术
- 批准号:
8117244 - 财政年份:2010
- 资助金额:
$ 73.42万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 73.42万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 73.42万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 73.42万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 73.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists